

Press Release



RaQualia Pharma and ASKA Pharmaceutical Sign Joint Research Agreement

TOKYO, November 1st, 2021 – ASKA Pharmaceutical Co., Ltd. (Headquarter: Minato-ku, Tokyo/ Representative Director: Sohta Yamaguchi), a subsidiary of ASKA Pharmaceutical Holdings Co., Ltd. (Headquarter: Minato-ku, Tokyo/ Representative Director: Takashi Yamaguchi), and RaQualia Pharma Inc. (Head Office: Nagoya, Aichi, Japan; President & CEO: Hirobumi Takeuchi) announced today that they have signed a new joint research agreement to develop new medications that are based on the ongoing joint research between the two companies regarding, drug discovery that targets specific ion channels.

The impact of this agreement on consolidated results for FY 2021 will be minor.

For details, please see attached sheet.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp



RaQualia Pharma Inc.
ASKA Pharmaceutical Co., Ltd.
November 1, 2021

RaQualia Pharma and ASKA Pharmaceutical Sign Joint Research Agreement

November 1, 2021 - RaQualia Pharma Inc. (Head Office: Nagoya, Aichi, Japan; President & CEO: Hirobumi Takeuchi; hereinafter referred to as "RaQualia Pharma") and ASKA Pharmaceutical Co., Ltd. (Head Office: Minato-ku, Tokyo; President and Representative Director: Sohta Yamaguchi; hereinafter referred to as "ASKA") announced today that they have signed a new joint research agreement ("Agreement") to develop new medications that are based on the ongoing joint research between the two companies regarding, drug discovery that targets specific ion channels (hereinafter referred to as "Joint Research").

RaQualia Pharma and ASKA have been conducting the Joint Research as stated above since July 2019 to develop new medications. As announced on July 13th, 2021, ASKA made a milestone payment to RaQualia Pharma, as the ongoing Joint Research ("Research Results") met the criteria set forth in the original agreement. Based on the Research Results, the two companies discussed the possibility about further joint research and came to an agreement regarding the next stage in the Joint Research, which has led to the conclusion of this Agreement.

Upon execution of the Agreement, ASKA will pay RaQualia Pharma an upfront payment as well as a collaborative research fee. RaQualia Pharma will also be eligible to receive a milestone payment based on the progress and achievements of the Joint Research. The specific conditions for achieving the milestones, as well as the associated payment amount, are not disclosed.

"We are very pleased to see the Joint Research between RaQualia Pharma and ASKA move to a new stage, as we also look forward to continuing working with ASKA using our drug discovery technologies in order to bringing innovative medications that address unmet medical needs to the clinic" commented Mr. Hirobumi Takeuchi, President and CEO of RaQualia Pharma.

Mr. Sohta Yamaguchi, President and Representative Director of ASKA, also commented, "We are very pleased that the Joint Research with RaQualia Pharma has advanced to a new stage, as we hope that the innovative medications developed through the collaboration between the two companies will address unmet medical needs."

The two companies will continue to combine their unique technological expertise in drug discovery research to achieve successful results.

About RaQualia Pharma

RaQualia Pharma Inc. has its research headquarters in Nagoya, Japan and is a research and development based pharmaceutical company whose aim is to create new pharmaceutical products with cutting-edge science and technology focusing on medical fields where patients have the greatest need. RaQualia create development compounds, the seeds for new drugs, via an open collaboration network which they have designed. RaQualia then deliver valuable new treatments to patients by licensing these compounds to partners who in turn bring that innovation to market.

For more information, please visit <https://www.raqualia.com/>.

About ASKA Pharma

Since its foundation in 1920, under the corporate philosophy of "Contribute toward the improvement of people's health and progress in society through the development of innovative products", ASKA has concentrated its management resources in three main therapeutic areas of internal medicine, obstetrics and gynecology, as well as urology, and is actively developing pharmaceutical products centered on new drugs to resolve medical needs.

For more information, please contact: <https://www.aska-pharma.co.jp/>

RaQualia Pharma Inc.
Corporate Planning
Phone: +81-(0)52-446-6100
E-mail: ask@raqualia.com

ASKA Pharmaceutical Co., Ltd.
Corporate Planning Department
Phone: +81-(0)3-5484-8366
E-mail: kouhou@aska-pharma.co.jp